Alkaline phosphatase flare with hyperostosis of bone metastases in lung adenocarcinoma treated with gefitinib

Abstract

Alkaline phosphatase (ALP) flare has been reported to occur during cancer treatment as a favorable event, particularly in the presence of bone metastasis. There have been only a few reports in lung cancer and associated radiographic findings have seldom been described. The authors observed ALP flare in a female patient with lung adenocarcinoma soon after the initiation of gefitinib. Moreover, on computed tomography, metastatic lesions of the rib and thoracic spine showed marked hyperostosis, with sizes larger than the original bone structure, suggesting efficacy of gefitinib. The significance of such hyperostosis should be elucidated.

Keywords

Alkaline phosphatase / bone metastasis / hyperostosis / gefitinib

References

[1] Coleman RE,Moss DW,Fogelman I.Biochemical prediction of response of bone metastases to treatment..Br J Cancer1988;58:205-10 PMCID:PMC2246751

[2] Arai Y.A case of lung cancer with alkaline phosphatase flare phenomenon during gefitinib therapy..Nihon Kokyuki Gakkai Zasshi2007;45:962-6(in Japanese)

[3] Hashisako M,Ikegami S,Nagata N.Flare phenomenon following gefitinib treatment of lung adenocarcinoma with bone metastasis..Tohoku J Exp Med2012;228:163-8

[4] Garfield D.Increasing osteoblastic lesions as a manifestation of a major response to gefitinib..J Thorac Oncol2006;1:859-60

[5] Lind JS,Smit EF.Osteoblastic bone lesions developing during treatment with erlotinib indicate major response in patients with non-small cell lung cancer: a brief report..J Thorac Oncol2010;5:554-7

[6] Yasuda Y,Ichikado K.Alkaline phosphatase flare phenomenon following epidermal growth factor-tyrosine kinase inhibitor treatment of non-small cell lung cancer: report of a case and case review..Respir Med Case Rep2014;13:51-3

[7] Chao HS,Chiu CH,Chen YM.Bone scan flare phenomenon in non-small-cell lung cancer patients treated with gefitinib..Clin Nucl Med2009;34:346-9

[8] Shimazaki C,Nakano S,Fuchida S,Okamoto M.High serum bone-specific alkaline phosphatase level after bortezomib-combined therapy in refractory multiple myeloma: possible role of bortezomib on osteoblast differentiation..Leukemia2005;19:1102-3

[9] Normanno N,Aldinucci D,Mancino M,De Fillippi R.Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: implications for the pathogenesis and treatment of bone metastasis..Endocr Relat Cancer2005;12:471-82

[10] Pluquet E,Legendre A,Souquet PJ,Perol M,Oliveiro G,Quoix E,Milleron B.Osteoblastic reaction in non-small cell lung carcinoma and its association to epidermal growth factor receptor tyrosine kinase inhibitors response and prolonged survival..J Thorac Oncol2010;5:491-6

[11] Yoshimoto A,Kimura H,Fujimura M.Transient liver injury caused by gefitinib..Nihon Kokyuki Gakkai Zasshi2004;42:56-61(in Japanese)